Lilly partners with China's Yabao on diabetes drug

Eli Lilly ($LLY) is partnering with Beijing-based Yabao Pharmaceuticals on the development of its early-stage diabetes drug LY2608204. In the deal Yabao gains development and commercialization rights in China, with Lilly holding on to unspecified buy-in rights to the big Asian market. Lilly didn't disclose any details on the deal for the glucokinase activator. These kinds of collaborations have been gaining ground in China in recent years, as local developers gain R&D experience. Release

Suggested Articles

Cancer biotech Zentalis Pharmaceuticals priced its IPO at $165 million, eclipsing the $100 million goal it laid out in early March.

The agreement gives Innovax access to a GSK adjuvant to enhance the immune response triggered by its recombinant protein-based vaccine.

Johnson & Johnson is paying Fate Therapeutics $50 million upfront to collaborate on up to four CAR NK and CAR-T cell therapies.